Oncotype DX vs MammaPrint vs EndoPredict — Breast Cancer Genomic Test Comparison & Calculator

Oncotype DX is a 21-gene genomic assay that calculates a Recurrence Score (RS) from 0 to 100 for early-stage, hormone receptor-positive (HR+), HER2-negative breast cancer. The TAILORx trial established that patients with RS 0–25 derive no benefit from adding chemotherapy to endocrine therapy, while those with RS 26–100 benefit significantly from chemotherapy. MammaPrint and EndoPredict are alternative genomic tests with different gene panels and clinical applications. This guide compares all three assays, explains their scoring systems and pivotal trial evidence, and helps clinicians determine which test is most appropriate for each clinical scenario.

Oncotype DX — The 21-Gene Recurrence Score

Oncotype DX is the most widely used genomic assay for early-stage breast cancer in the United States and carries an NCCN Category 1 recommendation for chemotherapy decision-making in HR+/HER2- disease. In the UK, NICE diagnostic guidance DG34 recommends Oncotype DX for ER-positive, HER2-negative, node-negative early breast cancer to guide chemotherapy decisions, alongside EndoPredict (DG42) and Prosigna as approved genomic tests. These tests are funded by the NHS for eligible patients.

How It Works

The assay measures expression of 21 genes — 16 cancer-related genes and 5 reference genes — from formalin-fixed paraffin-embedded (FFPE) tumour tissue using reverse transcription polymerase chain reaction (RT-PCR). The result is a continuous Recurrence Score (RS) from 0 to 100.

Key Trial Evidence

TAILORx (2018) — the landmark trial for node-negative disease:

• 10,273 women with HR+/HER2-/N0 breast cancer
• RS 0–10: Low risk — endocrine therapy alone (no randomisation needed)
• RS 11–25: Randomised to endocrine therapy ± chemotherapy — no benefit from chemotherapy in women over 50; modest benefit in women ≤50 with RS 21–25
• RS 26–100: Clear chemotherapy benefit (>13% absolute improvement in distant recurrence-free survival)

RxPONDER (2021) — extended evidence to node-positive disease:

• 5,083 women with HR+/HER2-, 1–3 positive lymph nodes, RS 0–25
• Postmenopausal women: No chemotherapy benefit (endocrine therapy alone non-inferior)
• Premenopausal women: Chemotherapy benefit observed (~5% absolute improvement), even with RS 0–25

Oncotype DX Score Interpretation

| RS Range | Node Status | Age Group | Chemotherapy Recommendation | |----------|------------|-----------|---------------------------| | 0–10 | N0 | Any | No benefit — endocrine therapy alone | | 11–15 | N0 | Any | No benefit — endocrine therapy alone | | 16–20 | N0 | ≤50 | Small benefit (~1.6%) — discuss with patient | | 21–25 | N0 | ≤50 | Substantial benefit (~6.5%) — chemotherapy usually recommended | | 11–25 | N0 | >50 | No benefit — endocrine therapy alone | | 26–100 | Any | Any | Clear benefit — chemotherapy recommended | | 0–25 | N1 (1–3 nodes) | Postmenopausal | No benefit — endocrine therapy alone | | 0–25 | N1 (1–3 nodes) | Premenopausal | Chemotherapy benefit — recommended |

MammaPrint — The 70-Gene Signature

MammaPrint uses a 70-gene expression profile to classify breast cancer into binary risk categories: low risk or high risk. It was the first FDA-cleared genomic test for breast cancer and has broader applicability than Oncotype DX.

How It Works

MammaPrint measures the expression of 70 genes associated with metastatic potential using DNA microarray technology. Unlike Oncotype DX's continuous score, MammaPrint provides a binary result — the tumour is classified as either genomically low risk or high risk based on a predefined signature threshold.

The test can be performed on fresh or FFPE tissue, offering flexibility in tissue handling compared with some competing assays.

Key Trial Evidence

MINDACT (2016) — the pivotal prospective validation trial:

• 6,693 women with early breast cancer (node-negative or 1–3 positive nodes)
• Patients classified as clinical high risk / genomic low risk were randomised to chemotherapy vs no chemotherapy
• 5-year distant metastasis-free survival without chemo: 94.7% — demonstrating that patients classified as genomic low risk can safely avoid chemotherapy even when clinical features suggest higher risk
• Benefit extended to patients with 1–3 positive lymph nodes

Broader Applicability

MammaPrint can be used for:

• HR+/HER2- tumours (like Oncotype DX)
• HR+/HER2+ tumours (unlike Oncotype DX, which is limited to HER2-)
• Node-negative and node-positive disease (up to 3 positive nodes)

This broader indication profile makes MammaPrint a useful option when the clinical scenario falls outside Oncotype DX's validated indications.

EndoPredict — The 12-Gene Score

EndoPredict measures 12 genes (8 cancer-related genes and 3 reference genes, plus a normalisation gene) and produces two distinct scores — a pure molecular score and the EPclin score, which integrates molecular data with tumour size and nodal status.

How It Works

The assay is performed on FFPE tissue using quantitative RT-PCR and produces:

1. EP score: The molecular-only component (12-gene expression)
2. EPclin score: Combines the EP score with tumour size (pT) and nodal status (pN) for a comprehensive risk assessment

An EPclin score below 3.3 indicates low risk of distant recurrence over 10 years; 3.3 or above indicates high risk.

Key Trial Evidence

EndoPredict has been validated in multiple retrospective-prospective analyses:

• ABCSG-6 and ABCSG-8 trials: Demonstrated strong prognostic performance in postmenopausal women with HR+/HER2-, node-negative or node-positive (1–3 nodes) breast cancer
• 10-year and 15-year follow-up data: EndoPredict showed particularly strong prediction of late distant recurrence (years 5–15), outperforming other assays in this time window

EndoPredict's Unique Strength: Late Recurrence Prediction

HR+/HER2- breast cancer has a well-recognised pattern of late recurrence — distant metastases can occur 10, 15, or even 20 years after diagnosis. While Oncotype DX primarily predicts 10-year recurrence risk, EndoPredict's EPclin score provides robust discrimination between patients at low vs high risk of late events beyond 5 years. This information is particularly valuable for decisions about extended endocrine therapy (continuing beyond the standard 5 years).

Head-to-Head Comparison

| Feature | Oncotype DX | MammaPrint | EndoPredict | |---------|------------|------------|-------------| | Genes tested | 21 | 70 | 12 | | Score range | 0–100 (continuous) | Low / High (binary) | EPclin (continuous) | | Key trial | TAILORx, RxPONDER | MINDACT | ABCSG-6/8 | | Node status | N0 (+ N1 with RxPONDER) | N0–N1 (up to 3 nodes) | N0–N1 | | Late recurrence | Moderate | Moderate | Strong | | HER2 status | HER2- only | HER2- and HER2+ | HER2- only | | Tissue required | FFPE (paraffin) | Fresh or FFPE | FFPE | | Turnaround | ~10–14 days | ~10 days | ~5–7 days | | NCCN recommended | Category 1 | Category 1 | Category 2A |

Key Takeaways from the Comparison

• Oncotype DX has the most extensive prospective evidence base, with both TAILORx and RxPONDER providing Level 1 evidence for chemotherapy benefit prediction
• MammaPrint offers the broadest applicability (including HER2+ tumours) and robust prospective data from MINDACT
• EndoPredict provides the fastest turnaround and strongest late recurrence prediction, with the added value of integrating clinical factors into the EPclin score

When to Use Each Test

The choice of genomic test depends on the clinical scenario, patient characteristics, and the specific clinical question being addressed.

HR+/HER2-/Node-Negative (N0)

Oncotype DX is the first-line choice in this scenario, supported by the largest body of prospective evidence (TAILORx). MammaPrint and EndoPredict are acceptable alternatives with strong supporting data.

HR+/HER2-/Node-Positive (1–3 nodes)

Oncotype DX (RxPONDER data) or MammaPrint (MINDACT data) — both have prospective evidence in node-positive disease. The choice may depend on menopausal status, as RxPONDER demonstrated a critical interaction between RS and menopausal status in node-positive patients.

Concern About Late Recurrence

EndoPredict provides the strongest evidence for predicting late distant recurrence (years 5–15). This is particularly relevant for patients considering extended endocrine therapy duration.

Need for Fast Results

EndoPredict has the fastest turnaround (~5–7 days), which can be advantageous when timely treatment decisions are needed.

HR+/HER2+ Tumours

MammaPrint is the only assay validated for use in HER2-positive tumours. Oncotype DX and EndoPredict are restricted to HER2-negative disease.

Using Genomic Score Calculators at Point of Care

Interpreting genomic test results requires integration with clinical factors — particularly age, menopausal status, and nodal status. OncoToolkit provides calculators to assist with interpretation:

• Oncotype DX Recurrence Score Calculator — Interpret RS by age and nodal status with TAILORx and RxPONDER guidance
• Breast Cancer Prognostic Panels — Integrate genomic risk with additional clinical factors for comprehensive prognostication

These calculators help clinicians contextualise genomic test results within the broader clinical picture, supporting informed shared decision-making with patients about chemotherapy benefit. OncoToolkit hosts over 130 oncology calculators spanning staging, prognosis, treatment toxicity, and supportive care.

Frequently Asked Questions

What is a good Oncotype DX recurrence score?

A Recurrence Score (RS) of 0–25 is considered low risk for node-negative patients based on the TAILORx trial. Women over 50 with RS 0–25 showed no chemotherapy benefit. For women aged 50 or younger, scores in the 16–25 range may show some benefit, particularly RS 21–25 where a ~6.5% absolute benefit was observed. Scores of 26–100 indicate high risk with clear chemotherapy benefit.

What is the difference between Oncotype DX and MammaPrint?

Oncotype DX analyzes 21 genes and produces a continuous score (0–100), validated primarily by TAILORx and RxPONDER. MammaPrint analyzes 70 genes and gives a binary result (low/high risk), validated by MINDACT. Oncotype DX is the most widely used in the US with NCCN Category 1 recommendation. MammaPrint has broader applicability including HER2-positive tumours and validation in node-positive disease up to 3 nodes.

Do I need chemotherapy if my Oncotype score is low?

For node-negative, HR+/HER2- breast cancer, TAILORx showed that patients with RS 0–25 (age >50) or RS 0–15 (age ≤50) do not benefit from chemotherapy. For node-positive disease (1–3 nodes), RxPONDER demonstrated that postmenopausal women with RS 0–25 can safely omit chemotherapy, while premenopausal women in the same range still benefit from its addition.

Which breast cancer genomic test is most accurate?

Each test excels in different areas. Oncotype DX has the strongest prospective evidence for chemotherapy benefit prediction in HR+/HER2- disease. MammaPrint has the broadest applicability across tumour subtypes and nodal status. EndoPredict provides the best late recurrence prediction (years 5–15). No single test is universally superior — the choice should match the clinical question.

What is the EndoPredict EPclin score?

The EPclin score combines EndoPredict's 12-gene molecular score with clinical factors (tumour size and nodal status) into a single continuous risk score. EPclin <3.3 indicates low risk and ≥3.3 indicates high risk of distant recurrence. Its unique strength is robust prediction of late recurrence (years 5–15), making it particularly useful for decisions about extended endocrine therapy.

This article is intended for healthcare professionals. Genomic test results should be interpreted within the context of individual patient characteristics, clinical stage, tumour biology, and multidisciplinary team discussion.